trending Market Intelligence /marketintelligence/en/news-insights/trending/RMcL5ffylDAE6PkoBc63ow2 content esgSubNav
In This List

Mitsubishi Tanabe to cancel licensing agreement with Kolon Life Science

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Mitsubishi Tanabe to cancel licensing agreement with Kolon Life Science

Mitsubishi Tanabe Pharma Corp. is looking to cancel a licensing agreement signed with Kolon Life Science Inc.

Mitsubishi Tanabe had been planning to acquire exclusive development and commercialization of Kolon's cell therapy Invossa, used for the treatment of knee osteoarthritis. Kolon would have received an upfront payment of ¥2.5 billion with future development and milestone payments and royalties on future sales.

Mitsubishi Tanabe has started negotiations with the Korea-based Kolon for the cancellation of the agreement and will provide the financial impact of the decision at a later date.

As of Dec. 19, US$1 was equivalent to ¥112.98.